Harrow, Inc. (HROW) News
Track canonical SquawkNews coverage tagged to HROW, Harrow, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Harrow targets $250M quarterly revenue by 2027; Leerink sets $45
Harrow outlined a five-year roadmap targeting $250M quarterly revenue by 2027, while Leerink Partners initiated coverage with an Outperform rating and a $45 price target.
EQUITY | Sep 14, 2026, 11:22 AM UTC
M
HROW targets $250M quarterly revenue by 2027 under long-term strategy
Management outlined a long-term, five-year strategic vision with a goal of $250 million quarterly revenue for 2027. Growth drivers cited include G-MELT, IHEEZO, and VEVYE, with expansion expected from new product launche
EQUITY | Sep 09, 2026, 08:16 PM UTC
L
Leerink initiates Harrow at Outperform, $45 target
Leerink Partners initiated Harrow with an Outperform rating and a $45.00/share price target.
EQUITY | Sep 09, 2026, 03:28 PM UTC
L
Harrow names Andrew R. Boll principal accounting officer
Harrow appointed Andrew R. Boll as principal accounting officer, effective September 4, 2026, following Randall E. Pollard's departure as chief accounting officer.
REGULATION | Sep 04, 2026, 08:54 PM UTC
L
Harrow management to participate in three September investor conferences
Harrow said management will participate in three investor conferences in September in New York, NY. The conferences are scheduled for 2026 Cantor Global Health…
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
HROW - Harrow to Participate in Three Investor Conferences in September
HROW - Harrow to Participate in Three Investor Conferences in September
EQUITY | Sep 01, 2026, 11:02 AM UTC
L
Harrow reports iheezo® patient discomfort results after intravitreal injections
Harrow announces iheezo® patient-reported discomfort data following intravitreal injections, citing lower discomfort at all post-injection assessments and statistically significant differences versus comparator at every
EQUITY | Aug 20, 2026, 11:08 AM UTC
L
HROW - Harrow Announces IHEEZO® Data in Patient -Reported Discomfort Following Intravitreal Injections
HROW - Harrow Announces IHEEZO® Data in Patient -Reported Discomfort Following Intravitreal Injections
EQUITY | Aug 20, 2026, 11:00 AM UTC
L
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
BTIG analyst Thomas Shrader reiterates Harrow (NASDAQ: HROW ) with a Buy and maintains $63 price target.
EQUITY | Aug 11, 2026, 06:03 PM UTC
L
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of OppFi Inc (NYSE: OPFI ) fell sharply in pre-market trading after the company reported worse-than-expected
EARNINGS | Aug 11, 2026, 12:04 PM UTC
L
Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M Est
Harrow (NASDAQ: HROW ) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $348.468 million estimate.
EARNINGS | Aug 10, 2026, 08:09 PM UTC
H
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Harrow Inc. (NASDAQ: HROW ) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ: VTRS ). Viatris To Sell Tyrvaya To Harrow In Up To $100 Million Deal Tyrvaya is a ch
EARNINGS | Aug 06, 2026, 05:56 PM UTC
L
HROW - Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA -Approved Nasal Spray for Dry Eye Disease
HROW - Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA -Approved Nasal Spray for Dry Eye Disease
REGULATION | Aug 06, 2026, 11:00 AM UTC
H
WBLR Updates Analyst Conviction List
Adds and removes stocks from conviction list
EQUITY | Aug 03, 2026, 11:59 AM UTC
L
HROW lows -3.5%
HROW lows -3.5%
EQUITY | Jul 20, 2026, 03:01 PM UTC
L
HROW Samsung Bioepis and Harrow Present Interim Data from a Large Scale Post Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Bio
HROW Samsung Bioepis and Harrow Present Interim Data from a Large Scale Post Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
EQUITY | Jul 20, 2026, 01:28 PM UTC
L
Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis
Harrow (NASDAQ: HROW ), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTI
REGULATION | Jul 01, 2026, 11:02 AM UTC